



(51) International Patent Classification:

A61K 31/4245 (2006.01) A61K 45/00 (2006.01)
A61K 9/00 (2006.01) A61P 9/00 (2006.01)
A61K 31/4402 (2006.01) A61P 9/04 (2006.01)

(21) International Application Number:

PCT/US2023/071610

(22) International Filing Date:

03 August 2023 (03.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/370,435	04 August 2022 (04.08.2022)	US
63/405,310	09 September 2022 (09.09.2022)	US
63/377,279	27 September 2022 (27.09.2022)	US
63/427,067	21 November 2022 (21.11.2022)	US
63/483,882	08 February 2023 (08.02.2023)	US
63/485,215	15 February 2023 (15.02.2023)	US
63/524,559	30 June 2023 (30.06.2023)	US

(71) Applicant: CYTOKINETICS, INCORPORATED

[US/US]; 350 Oyster Point Blvd, South San Francisco, California 94080 (US).

(72) Inventors: **MALIK, Fady**; c/o Cytokinetics, Incorporated, 350 Oyster Point Blvd, South San Francisco, California 94080 (US). **KUPFER, Stuart**; c/o Cytokinetics, Incorporated, 350 Oyster Point Blvd, South San Francisco, California 94080 (US). **JACOBY, Daniel Louis**; c/o Cytokinetics, Incorporated, 350 Oyster Point Blvd, South San Francisco, California 94080 (US). **HEITNER, Steven B.**; c/o Cytokinetics, Incorporated, 350 Oyster Point Blvd, South San Francisco, California 94080 (US). **MELLONI, Chiara**; c/o Cytokinetics, Incorporated, 350 Oyster Point Blvd, South San Francisco, California 94080 (US). **MENG, Lisa**; c/o Cytokinetics, Incorporated, 350 Oyster Point Blvd, South San Francisco, California 94080 (US). **WOHLTMAN, Qi**; c/o Cytokinetics, Incorporated, 350 Oyster Point Blvd, South San Francisco, California 94080 (US).

(74) Agent: **DAWSON, Thomas K.** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

(54) Title: METHODS FOR TREATING OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY




FIG. 1

(57) Abstract: Methods for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) are described herein. The treatment methods include the administration of a cardiac myosin inhibitor (CK-3773274, also referred to as CK-274 or aficamten) and may include titrating an administered daily dose based on one or more components of an echocardiogram. The daily dose may be increased, maintained, decreased, or terminated, based on the echocardiogram. The methods may be useful for treating patients who have been recently diagnosed with oHCM, patients who are treatment naive for oHCM, or patients who have previously received SOC medical therapy for oHCM and have discontinued said therapy prior to administration of aficamten, such as patients with chronic oHCM.

[Continued on next page]

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*